Holen Sie sich die Stockscreener-App
7.90
5.33%
0.40
Handel nachbörslich:
7.87
-0.03
-0.38%
Schlusskurs vom Vortag:
$7.50
Offen:
$7.62
24-Stunden-Volumen:
1.91M
Relative Volume:
0.60
Marktkapitalisierung:
$1.18B
Einnahmen:
$204.73M
Nettoeinkommen (Verlust:
$-184.29M
KGV:
-10.93
EPS:
-0.7226
Netto-Cashflow:
$-51.87M
1W Leistung:
+3.95%
1M Leistung:
+7.05%
6M Leistung:
+167.80%
1J Leistung:
+165.99%
1-Tages-Spanne:
$7.50
$7.92
1-Wochen-Bereich:
$7.325
$7.92
52-Wochen-Spanne:
$2.545
$9.42
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Firmenname
Maravai Lifesciences Holdings Inc
Sektor
Branche
Telefon
(858) 546-0004
Adresse
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
7.90 | 1.13B | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Neutral |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-08-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-01-05 | Herabstufung | UBS | Buy → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-11-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Eingeleitet | Credit Suisse | Outperform |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-15 | Eingeleitet | Jefferies | Buy |
| 2020-12-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-12-15 | Eingeleitet | Stifel | Buy |
| 2020-12-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-14 | Eingeleitet | UBS | Buy |
Alle ansehen
Maravai Lifesciences Holdings Inc Aktie (MRVI) Neueste Nachrichten
Maravai secures CleanCap patent and reports on Maravai LifeSciences stock - AD HOC NEWS
Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - uk.finance.yahoo.com
Maravai LifeSciences Holdings, Inc. (MRVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Millennium Management Reports 5.2% Stake in Maravai LifeSciences Holdings - Kalkine Media
More than 5% of Maravai LifeSciences (MRVI) shares are listed with shared voting power. - Stock Titan
Maravai LifeSciences stock gets a USD 8.00 UBS target - AD HOC NEWS
MRVI: Strong 1H 2026 growth and cost reductions drive a profitable, diversified life sciences platform - TradingView
Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers? - Yahoo Finance
Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In? - Yahoo Finance
Maravai LifeSciences stock gains 3.74 percent as market value reaches USD 326.82 million - AD HOC NEWS
Maravai LifeSciences stock falls after recent slide, investors eye latest results - AD HOC NEWS
Maravai LifeSciences Holdings (MRVI): Investor Outlook Reveals 2% Potential Upside Amidst Industry Growth - DirectorsTalk Interviews
Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal
Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) Stock Price, News & Analysis - kalkine.com.au
Maravai Lifesciences CEO Brust Bernd Forfeits 29,250 Shares at $7.32 Each (NASDAQ: MRVI) - Kalkine Media
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com South Africa
MRVI Maintained by UBS -- Price Target Raised to $8.00 - GuruFocus
UBS Adjusts Maravai Lifesciences Price Target to $8 From $2.50, Maintains Neutral Rating - Yahoo Finance
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel (MRVI) - Seeking Alpha
Maravai (NASDAQ: MRVI) CFO now holds 423K shares after tax withholding - Stock Titan
Maravai (MRVI) Technicals: Ends Up by 4.22% at $8.64 in Latest Trading - vinanet.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Why Maravai LifeSciences Holdings (MRVI) Stock Climbed After Its Latest Update - Sahm
Maravai Lifesciences stock reaches 52-week high of 8.15 USD By Investing.com - Investing.com Nigeria
Maravai Lifesciences stock reaches 52-week high of 8.15 USD - investing.com
Maravai (MRVI) Earnings Reading: EPS Prints Above Forecast in the Latest Reading; Closing Move: The Market Price Advances 25.78% in Latest TradingPost-Announcement Reaction - vinanet.vn
Maravai Lifesciences Up Over 30%, on Pace for Largest Percent Increase in Over a Year -- Data Talk - Bitget
MRVI Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineNew Analyst Coverage - vinanet.vn
Maravai Lifesciences Earnings Call Highlights Margin Rebound - TipRanks
MRVI Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 54.65%Post-Announcement Reaction - vinanet.vn
Maravai LifeSciences (MRVI) Slides 1.38% to $5.70 as Key Support Level Comes into FocusALMA Signal - vinanet.vn
Wall Street Zen Upgrades Maravai LifeSciences (NASDAQ:MRVI) to Buy - MarketBeat
Maravai (MRVI) Q2 2026 Earnings Call Transcript - AOL.com
Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake - Stock Titan
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Maravai Q2 2026 slides: margin expansion drives EBITDA guidance raise By Investing.com - Investing.com Nigeria
Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows - Quiver Quantitative
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Moomoo
MRVI Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $6.50 - GuruFocus
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - MarketBeat
Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platform - Bitget
Earnings call transcript: Maravai LifeSciences beats Q2 2026 estimates, shares fall - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation - DirectorsTalk Interviews
MRVI Looks 63.2% Overvalued on GF Value™ - GuruFocus
Is Maravai LifeSciences (MRVI) Overvalued After Q2 Earnings Miss? GF Score: 61/100 - GuruFocus
Maravai LifeSciences (MRVI) Plunges 9.92% as Shares Test Critical $5.35 Support ZoneFear Greed Extreme - dars.gov.et
Maravai LifeSciences Q2 Earnings Call Highlights - TradingView
Maravai LifeSciences Holdings Inc (MRVI) (Q2 2026) Earnings Call - GuruFocus
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Inv - The National Law Review
Finanzdaten der Maravai Lifesciences Holdings Inc-Aktie (MRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maravai Lifesciences Holdings Inc-Aktie (MRVI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORESHACK KURT | General Counsel |
Jun 09 '26 |
Sale |
5.06 |
25,000 |
126,500 |
360,767 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):